Japan Economic Newswire
The team including
Four million people in
The study was based on an analysis of the medical records of Alzheimer's patients who were given the drug and those who were not administered it.
The team plans to start clinical research with MCI patients this fall with
Dementia patients often develop vascular diseases and the team has noted that cilostazol enlarges the blood vessels to improve blood flow in the brain.
The team carried out a survey to check whether taking cilostazol in addition to dementia medications made any difference in the decline of cognitive functions in Alzheimer's patients, assigning scores on a 30-point scale.
Among those who can barely manage a social life, 36 people who were not taking cilostazol saw their scores fall by an average of 2.2 points over a year, compared with a 0.5 drop in 34 people who were taking the medicine. Improvements were even reported in some areas, but no effect was seen in patients with advanced conditions, the study said.
The team has discovered that cilostazol promotes excretion of waste products in the brain in mice with symptoms of Alzheimer's disease.
Other participants in the latest study include a research institute at the Kobe-based
Articles featured in Life Extension Daily News are derived from a variety of news sources and are provided as a service by Life Extension. These articles, while of potential interest to readers of Life Extension Daily News, do not necessarily represent the opinions nor constitute the advice of Life Extension.